Cite
Pharmacokinetics, Bioequivalence, and Safety Studies of a Generic Selective Tyrosine Kinase Inhibitor Nilotinib Capsule Versus a Branded Product in Healthy Chinese Volunteers.
MLA
Wang, Meng, et al. “Pharmacokinetics, Bioequivalence, and Safety Studies of a Generic Selective Tyrosine Kinase Inhibitor Nilotinib Capsule Versus a Branded Product in Healthy Chinese Volunteers.” Clinical Pharmacology in Drug Development, vol. 11, no. 10, Oct. 2022, pp. 1233–40. EBSCOhost, https://doi.org/10.1002/cpdd.1148.
APA
Wang, M., Zhu, Y., Huang, M., Wang, H., Zhou, W., Lu, D., & Zhang, Q. (2022). Pharmacokinetics, Bioequivalence, and Safety Studies of a Generic Selective Tyrosine Kinase Inhibitor Nilotinib Capsule Versus a Branded Product in Healthy Chinese Volunteers. Clinical Pharmacology in Drug Development, 11(10), 1233–1240. https://doi.org/10.1002/cpdd.1148
Chicago
Wang, Meng, Yifang Zhu, Ming Huang, Hao Wang, Wenjia Zhou, Dan Lu, and Quanying Zhang. 2022. “Pharmacokinetics, Bioequivalence, and Safety Studies of a Generic Selective Tyrosine Kinase Inhibitor Nilotinib Capsule Versus a Branded Product in Healthy Chinese Volunteers.” Clinical Pharmacology in Drug Development 11 (10): 1233–40. doi:10.1002/cpdd.1148.